Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations
← catalyst calendarNCT06915753 · readout ≤ 530 d
Sponsored by Tyra Biosciences, Inc (industry) · TYRA — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
100estimated
Sites
16
Countries
Canada, South Korea, Taiwan +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-04-24 | actual | When the study began enrolling |
| Primary completion | Jan 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Hepatocellular Carcinoma
- Solid Tumors
- Solid Tumor, Adult
- FGFR Gene Amplification
- FGFR Gene Alterations
- FGFR3 Gene Alteration
- FGFR3 Gene Mutation
- Advanced Solid Tumors
- FGFR4 Gene Mutation
- FGFR4 Gene Fusions
- FGF19 Gene Amplification
- FGF19 Gene Overexpression
- FGFR3 Gene Fusions
- Locally Advanced Unresectable Hepatocellular Carcinoma
Intervention
- Drug: TYRA-430
Primary outcomes
what the primary-completion date above is the date OFMaximum tolerated dose (MTD)
measured Up to 1 year
Rate and severity of adverse events of TYRA-430 as monotherapy
measured First dose of study drug through 28 days after the last dose of study drug
Recommended Phase 2 dose(s) of TYRA-430
measured Up to 2 years
Permalink · TYRA's whole pipeline · Catalyst calendar · Every registered study · What changed